BR112018001148A2 - heterômeros compreendendo proteínas de fusão com domínios de anticorpos - Google Patents
heterômeros compreendendo proteínas de fusão com domínios de anticorposInfo
- Publication number
- BR112018001148A2 BR112018001148A2 BR112018001148A BR112018001148A BR112018001148A2 BR 112018001148 A2 BR112018001148 A2 BR 112018001148A2 BR 112018001148 A BR112018001148 A BR 112018001148A BR 112018001148 A BR112018001148 A BR 112018001148A BR 112018001148 A2 BR112018001148 A2 BR 112018001148A2
- Authority
- BR
- Brazil
- Prior art keywords
- heteromers
- fusion proteins
- domain fusion
- antibody domain
- domain
- Prior art date
Links
- 102000037865 fusion proteins Human genes 0.000 title 1
- 108020001507 fusion proteins Proteins 0.000 title 1
- 230000004927 fusion Effects 0.000 abstract 1
- 108020001775 protein parts Proteins 0.000 abstract 1
- 230000012743 protein tagging Effects 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6437—Coagulation factor VIIa (3.4.21.21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
a presente invenção diz respeito a construtos de fusão de proteínas diméricas, nas quais as partes da proteína são fundidas tanto para o domínio ch1 do domínio cl de um anticorpo. esses construtos de fusão melhoram a estabilidade, a solubilidade, a meia-vida da circulação e o rendimento de produção da proteína dimérica.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
LU92791 | 2015-08-06 | ||
EP15180252 | 2015-08-07 | ||
PCT/EP2016/068730 WO2017021528A1 (en) | 2015-08-06 | 2016-08-05 | Heteromers comprising antibody domain fusion proteins |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112018001148A2 true BR112018001148A2 (pt) | 2018-09-11 |
Family
ID=56684637
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112018001148A BR112018001148A2 (pt) | 2015-08-06 | 2016-08-05 | heterômeros compreendendo proteínas de fusão com domínios de anticorpos |
Country Status (10)
Country | Link |
---|---|
US (1) | US20180216093A1 (pt) |
EP (1) | EP3331903B1 (pt) |
JP (1) | JP2018524995A (pt) |
KR (1) | KR20180038448A (pt) |
CN (1) | CN108350060A (pt) |
AU (1) | AU2016301962A1 (pt) |
BR (1) | BR112018001148A2 (pt) |
CA (1) | CA2993885A1 (pt) |
RU (1) | RU2018103173A (pt) |
WO (1) | WO2017021528A1 (pt) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JOP20200312A1 (ar) | 2015-06-26 | 2017-06-16 | Novartis Ag | الأجسام المضادة للعامل xi وطرق الاستخدام |
TW201802121A (zh) | 2016-05-25 | 2018-01-16 | 諾華公司 | 抗因子XI/XIa抗體之逆轉結合劑及其用途 |
BR112019012667A2 (pt) | 2016-12-23 | 2020-02-11 | Novartis Ag | Anticorpos do fator xi e métodos de uso |
CN110520152A (zh) * | 2017-03-14 | 2019-11-29 | 俄亥俄州创新基金会 | 与靶向组织因子的igg3免疫缀合物有关的方法和组合物 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2317727C (en) * | 1998-01-23 | 2013-01-08 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Multipurpose antibody derivatives |
WO2012170289A1 (en) * | 2011-06-03 | 2012-12-13 | The Regents Of The University Of Michigan | Method of producing factor viii proteins by recombinant methods |
-
2016
- 2016-08-05 CN CN201680046174.9A patent/CN108350060A/zh active Pending
- 2016-08-05 US US15/747,911 patent/US20180216093A1/en not_active Abandoned
- 2016-08-05 EP EP16751259.9A patent/EP3331903B1/en active Active
- 2016-08-05 BR BR112018001148A patent/BR112018001148A2/pt not_active Application Discontinuation
- 2016-08-05 CA CA2993885A patent/CA2993885A1/en not_active Abandoned
- 2016-08-05 JP JP2018504797A patent/JP2018524995A/ja not_active Withdrawn
- 2016-08-05 RU RU2018103173A patent/RU2018103173A/ru not_active Application Discontinuation
- 2016-08-05 AU AU2016301962A patent/AU2016301962A1/en not_active Abandoned
- 2016-08-05 WO PCT/EP2016/068730 patent/WO2017021528A1/en active Application Filing
- 2016-08-05 KR KR1020187002837A patent/KR20180038448A/ko unknown
Also Published As
Publication number | Publication date |
---|---|
EP3331903B1 (en) | 2019-10-02 |
AU2016301962A1 (en) | 2018-02-08 |
US20180216093A1 (en) | 2018-08-02 |
RU2018103173A (ru) | 2019-09-06 |
EP3331903A1 (en) | 2018-06-13 |
CA2993885A1 (en) | 2017-02-09 |
AU2016301962A9 (en) | 2018-02-22 |
WO2017021528A1 (en) | 2017-02-09 |
KR20180038448A (ko) | 2018-04-16 |
JP2018524995A (ja) | 2018-09-06 |
CN108350060A (zh) | 2018-07-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1124106T1 (el) | Συνθεσεις μεταφορεα-αντισωματος και μεθοδοι παρασκευης και χρησης αυτων | |
CY1124834T1 (el) | Αναστολεις της αλληλεπιδρασης της μηνινης-mll | |
CO2017011957A2 (es) | Variantes de alfa-amilasa y polinucleótidos que codifican las mismas | |
CL2018003136A1 (es) | Proteínas de unión específica y usos de las mismas. | |
DOP2018000259A (es) | Proteínas de unión biespecíficas que se unen a una proteína inmunomoduladora y a un antígeno tumoral | |
CL2019000261A1 (es) | Polipéptidos modificados y usos de los mismos. | |
CY1125392T1 (el) | Συνθεσεις και μεθοδοι γλυζυλιωσης πρωτεϊνων | |
EA201892561A1 (ru) | Гибридные белки gdf15 и их применение | |
CL2019001000A1 (es) | Proteínas de fusión fc heterodiméricas il15/il15ralfa | |
CO2018002450A2 (es) | Proteínas de fusión de gitrl y usos de las mismas | |
BR112017024384A2 (pt) | bactérias modificadas para reduzir hiperfenilalaninemia | |
BR112018012707A2 (pt) | inibidores da interação de menin-mll | |
PE20190563A1 (es) | Genes de mini-distrofina optimizados y casetes de expresion y su uso | |
CL2017001204A1 (es) | Derivados de 6-amino-7-biciclo-7-deaza-purina como inhibidores de la proteína quinasa | |
BR112018015485A2 (pt) | imunoglobulina fabs-in-tandem e usos da mesma | |
BR112017023374A2 (pt) | formulação de anticorpo anti-cgrp | |
EA201991168A1 (ru) | Белок, связывающий простатический специфический мембранный антиген | |
BR112016022841A2 (pt) | cadeia j modificada | |
BR112018001148A2 (pt) | heterômeros compreendendo proteínas de fusão com domínios de anticorpos | |
EA201690529A1 (ru) | Способы модификации клетки-хозяина | |
BR112018012262A2 (pt) | composições de interleucina-15 e seus usos | |
EA201501028A1 (ru) | Конструкции митохондриальных белков и их применение | |
CY1120824T1 (el) | Μεθοδοι αυξησης περιεχομενου μαννοζης ανασυνδυασμενων πρωτεϊνων | |
CY1124727T1 (el) | Πρωτεϊνες συντηξης tatk-cdkl5, συνθεσεις, φαρμακοτεχνικες μορφες και η χρηση αυτων | |
CO7270463A2 (es) | Composición farmacéutica acuosa que contiene un agente terapéutico biológico y guanidina o un derivado de la guanidina y una inyección que incluye la composición |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |